- Home
- PHAR vs NDMO Comparison
PHAR vs NDMO Comparison
Compare PHAR & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- NDMO
- Stock Information
- Founded
- PHAR 1988
- NDMO 2019
- Country
- PHAR Netherlands
- NDMO United States
- Employees
- PHAR N/A
- NDMO N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- NDMO Trusts Except Educational Religious and Charitable
- Sector
- PHAR Health Care
- NDMO Finance
- Exchange
- PHAR Nasdaq
- NDMO Nasdaq
- Market Cap
- PHAR 1.0B
- NDMO 620.6M
- IPO Year
- PHAR N/A
- NDMO N/A
- Fundamental
- Price
- PHAR $14.68
- NDMO $10.39
- Analyst Decision
- PHAR Strong Buy
- NDMO
- Analyst Count
- PHAR 3
- NDMO 0
- Target Price
- PHAR $30.00
- NDMO N/A
- AVG Volume (30 Days)
- PHAR 11.4K
- NDMO 218.6K
- Earning Date
- PHAR 10-23-2025
- NDMO 01-01-0001
- Dividend Yield
- PHAR N/A
- NDMO 6.75%
- EPS Growth
- PHAR N/A
- NDMO N/A
- EPS
- PHAR N/A
- NDMO N/A
- Revenue
- PHAR $339,836,000.00
- NDMO N/A
- Revenue This Year
- PHAR $16.63
- NDMO N/A
- Revenue Next Year
- PHAR $6.77
- NDMO N/A
- P/E Ratio
- PHAR N/A
- NDMO N/A
- Revenue Growth
- PHAR 22.44
- NDMO N/A
- 52 Week Low
- PHAR $7.10
- NDMO $8.99
- 52 Week High
- PHAR $17.08
- NDMO $11.24
- Technical
- Relative Strength Index (RSI)
- PHAR 57.93
- NDMO 72.17
- Support Level
- PHAR $13.51
- NDMO $9.72
- Resistance Level
- PHAR $15.61
- NDMO $9.98
- Average True Range (ATR)
- PHAR 0.90
- NDMO 0.11
- MACD
- PHAR -0.05
- NDMO 0.07
- Stochastic Oscillator
- PHAR 62.58
- NDMO 88.55
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.